Skip to main content
. 2018 Oct 25;9:258–277. doi: 10.1016/j.isci.2018.10.021

Figure 2.

Figure 2

Mutation Signatures of Post-anti-PD-1 Treatment Hyperprogressor Tumors

(A–C) (A) Commonly mutated genes in the two hyperprogressor tumors, (B) specific mutated genes in Patient 1's hyperprogressor tumor, and (C) specific mutated genes in Patient 2's hyperprogressor tumor. See also Figure S1, Tables S1 and S3.